Your browser does not support JavaScript!
分類清單
生技產業創新創業人才培育課程

系所行事曆
黃琤

專任副教授 

黃琤     

Cheng Huang

 

 

聯絡方式 學歷

☏ 02-2826-7149 (Office);

02-2826-7000 轉5923 (Lab)

 chengh@ym.edu.tw

〒 Institute of Biotechnology in Medicine, National Yang Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei City 112, Taiwan (R.O.C.)

2003 - 2007 Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Ph. D.


2000 - 2002 Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, M. S.

1995 - 1999 Department of Medical Technology, National Taiwan University College of Medicine, B. S.

 經歷
2017 - present Associate Professor, Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University
 
2015-2017  Associate Research Fellow, National Research Institute of Chinese Medicine
 
2011-2015  Assistant Research Fellow, National Research Institute of Chinese Medicine
 
2009-2011 Distinguished Postdoctoral Fellow of NSC (國科會-特約博士後研究學者), Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine  
 
2007 - 2009 Postdoctoral Fellow, Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine
 
研究方向
本實驗室主要研究目的有以下兩個大方向:
  1. 們的研究在於探討肝炎病毒之生活史及其致病機轉,希望透過對這些病毒之瞭解,能開發治療肝炎病毒之新藥。B型肝炎病毒(HBV)會造成人類肝臟急性或慢性的感染;並伴隨著嚴重的肝臟疾病,例如肝硬化及肝癌。D型肝炎病毒(HDV)會與B型肝炎病毒(HBV)共同感染(co-infection)或重疊感染(super-infection),引起嚴重的慢性肝炎,甚至猛爆性肝炎。我們希望瞭解在B型及D型肝炎病毒感染初期,研究宿主細胞運輸作用參與在B型及D型肝炎病毒生活史中的功能角色,進一步,我們也將研究B型及D型肝炎病毒在宿主細胞上的受體NTCP蛋白與病毒之間的作用關係。透過這個研究,除了有助於B型及D型肝炎病毒致病機轉的了解之外,並且可作為病毒藥物開發的模式。
  2. 目前已知肥胖和胰島素失調與許多疾病間存在關聯性,例如心血管疾病、第二型糖尿病、脂肪肝等等,這類疾病常涉及脂類代謝異常或醣類代謝異常。舉例而言,脂肪肝屬於非酒精性脂肪肝疾病的初始階段,是一種現代人常見的代謝症狀,主要是由脂質代謝失衡所造成。目前已有為數不少的臨床經驗顯示,脂肪肝會導致肝硬化,並且伴隨著脂肪性肝炎及肝壞死等問題的發生。我們的研究在於發展新藥在治療代謝疾病之用途,利用疾病小鼠之模型,希望可以改善多種新陳代謝疾病
  1.     Hepatitis B virus (HBV) causes acute and chronic infections in humans; such infections are often associated with severe liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). Hepatitis delta virus (HDV) causes fulminant hepatitis and progressive chronic liver cirrhosis in patients superinfected or coinfected with HBV. We examined the roles of clathrin-mediated trafficking pathway involved in the life cycle of HBV/HDV. In addition, the receptor on the plasma membrane which is required for the infection of HBV/HDV is NTCP. We have established HBV/HDV infection model in vitro and in vivo. Our model will help us to develop new drugs for treatment of HBV/HDV infection. Our study suggests new strategies for manipulating HBV/HDV for therapeutic purposes in treating disorders associated with liver injury and cirrhosis.
  2.      Obesity and dysregulated insulin action in the liver are strongly associated and are currently a worldwide health problem. Fatty liver, the initial stage of nonalcoholic fatty liver disease (NAFLD), is a common metabolic symptom, and is caused by an imbalance of lipid metabolism. The purpose of our proposal is to develop drugs for metabolic syndrome. We will design a process of pharmacology experiments for development of new drugs. In addition, we will complete additional safety evaluation for new drugs.
研究著作
  1. Han-Min Chen, Lin-Chien Lee, Kuang-Yu Hu, Wei-Jern Tsai, Cheng Huang, Hui-Jen Tsay, Hui-Kang Liu. (2018) The Application of Post-Translational Modification Oriented Serum Proteomics to Assess Experimental Diabetes with Complications. PLOS ONE. [Accepted]

  2. Jui-Chieh Chen, Cheng Huang, I-Neng Lee, Yu-Ping Wu, Chih-Hsin Tang. (2018) Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway. Molecular Carcinogenesis. doi: 10.1002/mc.22899. [Epub ahead of print]

  3. Yu-Heng Lai, Cheng-Pu Sun, Hsiu-Chen Huang, Jui-Chieh Chen, Hui-Kang Liu and Cheng Huang*. (2018) Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric. BMC Complementary and Alternative Medicine. 18:248-254 (* Corresponding author)

  4. Liu GT, Kung HN, Chen CK, Huang C, Wang YL, Yu CP, Lee CP. (2018) Improving nuclear envelope dynamics by EBV BFRF1 facilitates intranuclear component clearance through autophagy. FASEB Journal. 32(7):3968-3983

  5. Hsiu-Chen Huang, Hsu-Feng Lu, Yu-Heng Lai, Chung-Pei Lee, Hui-Kang Liu, and Cheng Huang*. (2018) Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. Antiviral Research. 150:69-78 (* Corresponding author)

  6. Huang HC, Lee CP, Liu HK, Chang MF, Lai YH, Lee YC, Huang C*. (2016) Cellular Nuclear Export Factors TAP and Aly Are Required for HDAg-L-mediated Assembly of Hepatitis Delta Virus. Journal of Biological Chemistry. 291(50):26226-26238. (* Corresponding author)

  7. Tseng TS, Chuang SM, Hsiao NW, Chen YW, Lee YC, Lin CC, Huang C, Tsai KC. (2016) Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. Molecular Biosystems. 12(8):2541-51. doi: 10.1039/c6mb00229c.

  8. Huang C, Wei YX, Shen MC, Tu YH, Wang CC, Huang HC. (2016) Chrysin, Abundant in Morinda citrifolia Fruit Water-EtOAc Extracts, Combined with Apigenin Synergistically Induced Apoptosis and Inhibited Migration in Human Breast and Liver Cancer Cells.  Journal of Agricultural and Food Chemistry. 64:4235-45 

  9. Cheng Huang, Chung-Kuang Lu, Ming-Chin Tu, Jia-Hua Chang, Yen-Ju Chen, Yu-Hsuan Tu, and Hsiu Chen Huang. (2016) Polyphenol-rich Avicennia marina leaf extracts induce apoptosis in human breast and liver cancer cells and in a nude mouse xenograft model. Oncotarget. doi: 10.18632/oncotarget.8624. 
  10. Hui-Kang Liu, Tzu-Min Hung, Hsiu-Chen Huang, I-Jung Lee, Chia-Chuan Chang, Jing-Jy Cheng, Lie-Chwen Lin, and Cheng Huang*. (2015) Bai-Hu-Jia-Ren-Shen-Tang Decoction Reduces Fatty Liver by Activating AMP-activated Protein Kinase In Vitro and In Vivo. Evidence-Based Complementary and Alternative Medicine. doi:10.1155/2015/651734 doi:10.1155/2015/651734  (* Corresponding author) 
  11. Cheng Huang, Yi-Jing Chen, Wei-Jen Chen, Chih-Li Lin, Yu-Xuan Wei, and Hsiu-Chen Huang. (2014) Combined treatment with chrysin and 1,2,3,4,6-penta-O-galloyl-β-D-glucose synergistically inhibits LRP6 and Skp2 activation in triple-negative breast cancer and xenografts. Molecular carcinogenesis. 54:1613-25 
  12. Hsiu-Chen Huang, Mi-Hua Tao, Tzu-Min Hung, Jui-Chieh Chen, Zi-Jun Lin, Cheng Huang*. 2014(-)-Epigallocatechin-3-gallate Inhibits Entry of Hepatitis B Virus into Hepatocytes. Antiviral Research. 111:100-111 (* Corresponding author) 
  13. Sheng-Fan Wang, Yueh-Ching Chou, Nirmal Mazumder, Fu-Jen Kao, Leslie D. Nagy, F. Peter Guengerich, Cheng Huang, Hsin-Chen Lee, Ping-Shan Lai, Yune-Fang Ueng. (2013) 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells.  Biochemical Pharmacology 15;86(4):548-60.
  14. Huang C, Lee SY, Lin CL, Tu TH, Chen LH, Chen YJ, and Huang HC. (2013) Co-treatment with Quercetin and 1,2,3,4,6-Penta-O-galloyl-β-d-glucose Causes Cell Cycle Arrest and Apoptosis in Human Breast Cancer MDA-MB-231 and AU565 Cells. Journal of Agricultural and Food Chemistry 61: 6430−6445 
  15. Cheng Huang, Jia-Yin Jiang, Shin C. Chang, Yeou-Guang Tsay, Mei-Ru Chen, and Ming-Fu Chang. (2012) NESI Protein Forms Complexes with Lamin A/C-Nups to Mediate the CRM1-Independent Nuclear Export of Large Hepatitis Delta Antigen. Journal of Virology. 87:1596-604 
  16. Pei-Yun Chuang, Cheng Huang, and Hsiu-Chen Huang. (2012) The use of a combination of tamoxifen and doxorubicin synergistically to induce cell cycle arrest in BT483 cells by down-regulating CDK1, CDK2 and cyclin D expression. Journal of Pharmaceutical Technology & Drug Research 2: 1-4
  17. Hsiu-Chen Huang, Chun-Chi Chen, Wen-Cheng Chang, Mi-Hua Tao, and Cheng Huang*. (2012) Entry of Hepatitis B Virus into Immortalized Human Primary Hepatocytes by Clathrin-Dependent Endocytosis. Journal of Virology. 86:9443-9453 (* Corresponding author) 
  18. Shih-Han Sun, Hsiu-Chen Huang, Cheng Huang, Jen-Kun Lin. (2012) Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. European Journal of Pharmacology. 690:22-30
  19. Cheng Huang, Shin C. Chang, Hui-Chin Yang, Chung-Liang Chien, and Ming-Fu Chang (2009) Clathrin-mediated post-Golgi trafficking in the morphogenesis of hepatitis delta virus. Journal of Virology. 83:12314-12324 
  20. Tzu-Min Hung, Shin C. Chang, Wei-Hsuan Yu, Yu-Wen Wang, Cheng Huang, Shao-Chun Lu, Po-Huang Lee, and Ming-Fu Chang (2009) A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. Hepatology. 50:1184-1193
  21. Cheng Huang, Shin C. Chang, I-Chen Yu, Yeou-Guang Tsay, and Ming-Fu Chang (2007) Large hepatitis delta antigen is a novel clathrin adaptor-like protein. Journal of Virology. 81:5985-5994. A Highlights from JV Selection. 
  22. Yun-Hsin Wang, Shin C. Chang, Cheng Huang, Ya-Ping Li, Chia-Huei Lee, and Ming-Fu Chang. (2005) Novel nuclear export signal interacting protein, NESI, critical for the assembly of hepatitis delta virus. Journal of Virology. 79:8113-8120 
專利
  1. 具有GLP-1受體調控活性之化合物及其用途。(中華民國專利證號I1025-0002-TW;大陸專利證號I1025-0002-CN
  2. 錫蘭七指蕨、入地蜈蚣素及黃酮類化合物用於治療或預防新陳代謝疾病之用途。(中華民國專利證號 I1025​-0004-TW